Instructions for Single-Domain Antibody Discovery

Creative Biolabs elaborates on single-domain antibody (sdAb) development and sequencing, which are designed to support scientists and pharmaceutical companies in their new drug discovery programmes.

Single domain antibodies are emerging arrows pointing at prevalent therapeutic targets and scarce ones involved in cancer, neurodegenerative disorders, and infections. Creative Biolabs introduces their sdAb discovery and profiling solutions, which contribute to harnessing the full potential of sdAbs.

"A full suite of antibody discovery, from initial discovery to advanced development stages, is provided and customised to meet each project's specifics, thus ensuring an infallible delivery." According to a scientist at Creative Biolabs.

sdAb Library Construction and Screening: Laying the Foundation

Creative Biolabs creates immunised sdAb libraries of 10–100 million clones through immunised camel, llama, alpaca, or shark and synthetic sdAb libraries by randomising the CDR1 and CDR3 using trimer codon technology. The screening process is meticulously designed to identify the most promising candidates, significantly enhancing efficiency and success rates.

Case: Anti-BBB sdAb DiscoveryAnti-BBB sdAb Discovery Service

Breaking through the blood-brain barrier (BBB) has long been a challenge. Creative Biolabs addresses this challenge by focusing on sdAbs that can effectively penetrate the BBB, positively implying the development of biologic-based treatments for brain disorders.

"We can also target endogenous transport systems, including carrier-mediated transporters like glucose and amino acid carriers, receptor-mediated transcytosis for insulin, transferrin, or low-density lipoproteins, and active efflux transporters such as p-glycoprotein." The scientist added.

De Novo sdAb Sequencing: Search to the Bottom

The de novo sdAb sequencing is based upon the exclusive Database Assisted Shotgun Sequencing (DASS) system that Creative Biolabs manages to precisely read the sequence information of soluble and functional sdAbs with diverse origins—with 100% coverage and 100% accuracy.

"For example, mass spectrometric de novo sequencing can yield the whole camelid heavy chain antibody sequence. Leu/Ile discrepancies can be addressed by homology comparisons with known VHH sequences. Furthermore, sdAb conjugates or immobilised sdAbs are also sequenced effectively using our DASS method." The scientist commented.

For more information about Creative Biolabs and their single-domain antibody services, please visit their official website: https://www.creative-biolabs.com/.

About Creative BiolabsCreative Biolabs is a leading biotechnology company specializing in CAR-T cell therapy development, gene therapy, and immunotherapy solutions. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality products and services to support biomedical research and drug development worldwide.

A fan of biotechnology who likes to post articles in relevant fields regularly